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AbsTrACT
background Opioid overdose is a major and increasing 
cause of injury and death. There is an urgent need for 
interventions to reduce overdose events among high-risk 
persons.
Methods Adults at elevated risk for opioid overdose 
involving heroin or pharmaceutical opioids who had 
been cared for in an emergency department (ED) were 
randomised to overdose education combined with a 
brief behavioural intervention and take-home naloxone 
or usual care. Outcomes included: (1) time to first opioid 
overdose-related event resulting in medical attention or 
death using competing risks survival analysis; and (2) ED 
visit and hospitalisation rates, using negative binomial 
regression and adjusting for time at risk.
results During the follow-up period, 24% of the 241 
participants had at least one overdose event, 85% 
had one or more ED visits and 55% had at least one 
hospitalisation, with no significant differences between 
intervention and comparison groups. The instantaneous 
risk of an overdose event was not significantly lower for 
the intervention group (sub-HR: 0.83; 95% CI 0.49 to 
1.40).
Discussion These null findings may be due in part 
to the severity of the population in terms of housing 
insecurity (70% impermanently housed), drug use, 
unemployment and acute healthcare issues. Given the 
high overdose and healthcare utilisation rates, more 
intensive interventions, such as direct referral and 
provision of housing and opioid agonist treatment 
medications, may be necessary to have a substantial 
impact on opioid overdoses for this high-acuity 
population in acute care settings. 
Trial registration number NCT0178830; Results.
InTroDuCTIon
Opioid overdose deaths continue to increase and 
are a major cause of preventable death.1 According 
to the CDC, opioid-involved overdose deaths 
quadrupled from 1999 to 2015 when there were 
33 091 such deaths in the USA.2 Additionally, 
opioid-related emergency department (ED) visits 
and inpatient admissions have increased dramat-
ically over the years reflecting the increase in 
non-fatal overdose.3 Many overdoses are amenable 
to intervention due to biological and social circum-
stances.4 Opioid overdoses rarely lead to sudden 
death, with death usually occurring several hours 
after consumption,5 though this may be changing 
as illicit synthetic opioids with their rapid rates of 
onset and high potency emerge as major causes 
of death.6 Moreover, most overdoses occur in the 
presence of another person,7 8 providing an oppor-
tunity for bystander intervention.
Brief behaviour change counselling is based on 
motivational interviewing (MI),9 has been found 
to help reduce drug use frequency10 and to signifi-
cantly improve health behaviours such as alcohol 
use and injury, to increase entry into drug abuse 
treatment and to reduce costs in ED.11 12 In phar-
maceutical opioid using patients in the ED with 
elevated risk for overdose, patients receiving a brief 
behavioural intervention had decreased overdose 
risk behaviours.13 Additionally, brief intervention 
has been used to decrease drug use among patients 
in the ED.14 However, these studies did not specif-
ically target illicit opioid use and did not combine 
brief behaviour change counselling with take-
home naloxone. We combined these interventions 
based on the information–motivation–behaviour 
model, positing that overdose education, combined 
with self-identified motivating factors and the 
behavioural skills to utilise naloxone, might impact 
overdose occurrence.15
Naloxone is an opioid-antagonist prescription 
medication that reverses opioid overdoses by pref-
erentially binding to opioid receptors and displacing 
opioids such as heroin, morphine, oxycodone 
and fentanyl and reversing respiratory depression 
and sedation. Naloxone cannot be abused, has 
no psychoactive effects and has been found to be 
extremely safe.16 17 Since the 1990s, naloxone has 
increasingly been provided to people who use drugs 
through low-threshold service programmes such 
that by 2014 community-based programmes were 
distributing naloxone to laypersons at 644 sites 
in the USA.18 Take-home naloxone for lay people 
has been recommended by organisations such as 
the WHO and in the Substance Abuse and Mental 
Health Services Administration opioid overdose 
toolkit.19 20
Research on take-home naloxone provided to 
people at risk for having or witnessing an overdose 
indicates that: (1) naloxone administration has not 
resulted in dangerous health consequences21; (2) 
lay persons can be trained to recognise an overdose 
and evaluate whether administration of naloxone 
is warranted as well as medical experts22; (3) illicit 
drug users are willing to administer naloxone to 
each other23; (4) naloxone availability does not 
increase drug use24; (5) many opioid overdoses 
have been reversed with naloxone as a result of 
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overdose prevention and recognition training combined with 
the distribution of take-home naloxone25; and (6) provision 
of naloxone is associated with reduced mortality in communi-
ties that implement the programme compared with communi-
ties that do not and reduced opioid overdose mortality after 
release from prison.25 26 However, there are no trials that aim 
to assess the impact of pairing naloxone provision with a brief 
behavioural intervention in healthcare settings on subsequent 
overdose events and healthcare utilisation.
ED and acute care settings are potentially advantageous 
settings to reach populations vulnerable to opioid overdose that 
may not access healthcare in other settings such as substance 
use disorder treatment centres or primary care. In this study, we 
tested an intervention for opioid users at elevated risk for over-
dose that was delivered during or after an acute care episode that 
combined opioid overdose education, a take-home naloxone kit 
and brief behaviour change counselling to determine the impact 
on participants’ subsequent opioid overdoses, ED visits and 
hospitalisations.
MeThoDs
setting
Participants were enrolled subsequent to a visit at one of two 
EDs in Seattle: Harborview Medical Center (HMC) and the 
University of Washington Medical Center (UWMC). HMC is 
a large urban academic medical centre dedicated to an under-
served population including those with mental health and 
substance use problems. UWMC is an academic tertiary care 
hospital providing extensive specialty care. Potential participants 
were identified through medical records review by study staff or 
healthcare staff referrals. Recruitment and enrolment generally 
occurred between the hours of 12:00 and 20:00 weekdays in the 
ED, in other hospital units during subsequent inpatient admis-
sion or at respite care (a recuperative care facility adjacent to 
HMC for homeless people who require medical assistance and 
shelter and do not require inpatient treatment).
Participants
Potential participants were identified either by study staff 
reviewing electronic medical records or by medical staff referral 
with eligibility confirmed via a screening questionnaire. Eligi-
bility criteria included being at elevated risk of opioid overdose 
based on: (1) reason for visit was opioid overdose; (2) use of 
pharmaceutical opioids not prescribed two or more times in the 
prior month; (3) use of other opioids, alcohol, sedatives or stim-
ulants within 2 hours of using opioids two or more times in the 
prior month; (4) average daily dose of prescribed opioids greater 
than 10 mg morphine equivalent dose or higher for 15 or more 
of the last 30 days; or (5) enrolled in an opioid agonist therapy 
(OAT) programme and receiving methadone or buprenorphine. 
Opioids needed to be used at least twice in the last 30 days (or 
if institutionalised recently, in the most recent month they were 
not institutionalised) with pharmaceutical users also needing 
to have other risks present. Subjects were not excluded if preg-
nant and were offered naloxone if in the intervention arm and 
informed during consent about potential risks to a fetus due to 
precipitated withdrawal and the need to seek emergency medical 
care.
Exclusion criteria included: (1) refusing access to follow-up 
medical or drug treatment records; (2) inability to communicate 
in English; (3) current suicidal ideation; (4) significant cogni-
tive or psychiatric impairment; (5) inability to provide adequate 
contact information to assist with follow-up (the number of 
required contacts was reduced after a month of recruitment from 
three to one as most homeless people were being excluded that 
would have negatively impacted the generalisability of the find-
ings); (6) under age 18 years or over age 70 years; (7) not living 
in Washington State or planning to move from Washington State 
within a year; (8) receiving treatment for sexual assault; or (9) 
currently having non-expired naloxone.
Potential participants provided informed consent for eligi-
bility screening. If eligible and interested in the study, consent 
was obtained for study participation. Eligibility screening and 
study participation were remunerated with $5 and $20 store gift 
cards, respectively. Follow-up surveys were conducted at 3, 6 
and 12 months (with $10, $10 and $20 gift card remunerations, 
respectively); these data are not presented here as follow-up 
rates were below 50% at each time point. Releases of informa-
tion and HIPAA (Health Insurance Portability and Accountability 
Act) authorisations were obtained to access medical records and 
drug treatment data. Baseline data were collected by interven-
tionists in clinical settings, with an attempt to maximise privacy, 
and participants were randomised; this process took approxi-
mately 30–45 min. An unrestricted or ‘fair-coin’ randomisation 
process was used to generate a study assignment table based on 
study identification numbers and implemented automatically via 
Research Electronic Data Capture (REDCap) with intervention-
ists learning study assignment at the same time as the participant.
Study data were collected and managed using REDCap elec-
tronic data capture, secure web-based tools hosted at the Institute 
of Translational Health Sciences at the University of Washington.
Intervention
The intervention consisted of (1) overdose education, (2) a brief 
behavioural change counselling component to assist partici-
pants in identifying their overdose risks and the steps they were 
interested in taking to reduce those risks and (3) a naloxone kit. 
The intervention was provided by two interventionists who had 
master’s degree and at least basic training in MI.
Overdose education included watching an 8 min video and 
reviewing an informational flier with the interventionist, which 
addressed risk factors for an opioid overdose, overdose recogni-
tion, recommendation to call 911, how to administer naloxone 
and guidance to remain with the overdose victim for several 
hours. The flier also provided specific information about loca-
tions where naloxone could be obtained either free at area 
syringe exchange programmes or for purchase at a local phar-
macy. The flier included a link to www. stopoverdose. org, which 
has online overdose educational materials, including the training 
video used at the time created by the New York City Department 
of Health as well as a naloxone locator for Washington State.
Naloxone administration training included hands-on practice 
assembling the kit,which included a luer lock syringe, 2 mg/2 mL 
naloxone (Amphastar NDC#76329-3369-1) and a mucosal 
atomisation device. Intranasal administration was an off-label 
route of administration, and a Food and Drug Administration 
Investigational New Drug application was required (#112 043). 
The kit included two doses of naloxone, two mucosal atomisers, 
a disposable rescue breathing mask, a wallet card with informa-
tion about Washington State’s Good Samaritan Overdose and 
naloxone access law (RCW 69.50.315) and the educational flier 
all packaged in a nylon pouch. Participants were directly handed 
the kit by study staff; however, they did not need to accept the 
offer of the kit to be considered a study participant.
Participants assigned to the comparison group were provided 
the informational flier.
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Figure 1 CONSORT diagram, study enrolment, allocation and analysis. CONSORT, Consolidated Standards of Reporting Trials.
Intervention fidelity
Sessions were audio-recorded, and initial training and regular 
supervision with a doctoral level psychologist (CD) occurred 
throughout the study. A sample of intervention recordings were 
reviewed for fidelity. The intervention was MI)inspired in order 
to facilitate rapport building and participant engagement. Despite 
not being a full MI intervention, given the didactic and interac-
tive educational components, fidelity was measured using scales 
from the Motivational Interviewing Treatment Integrity 3.1.1. 
Interventionist behavioural counts were measured along with MI 
Spirit, an average measure of the quality of MI delivery.27
Data sources
The baseline survey included demographic information, housing 
status and relationship status. Opioid use in the prior 30 days was 
categorised as: only pharmaceutical opioids whether prescribed 
to the participant or not, OAT from an approved provider (licit 
source), heroin and OAT, and OAT no heroin. Route of adminis-
tration was coded into whether a person had smoked, snorted or 
injected any opioids (96% reported injecting). Days of opioid use 
in the prior 30 days was recorded. Protective factors, including 
whether ‘anyone you have regular contact with’ had ‘overdose 
education’ or ‘regularly carry or have quick access to naloxone’, 
were documented. Overdose risk factors included: overdose 
history; using opioids when no one else was around or behind 
a locked door; and using opioids within 2 hours of alcohol, 
sedatives/downers (specific brand names were provided), using 
another kind of opioid or stimulants including cocaine, metham-
phetamine or pharmaceutical stimulants.
Healthcare utilisation data from UW Medicine included 
encounter and billing data from HMC and UWMC, their EDs 
and affiliated onsite and offsite clinics in the Seattle, Washington, 
metropolitan area.
The Comprehensive Hospital Abstract Reporting System 
(CHARS) maintained by the Washington State Department of 
Health was used for statewide capture of opioid overdose events 
resulting in inpatient or hospital observation stays. CHARS 
contains hospital discharge information for inpatient and obser-
vation stays derived from billing records for essentially all Wash-
ington State community hospitals. Statewide death certificate 
data were obtained from the Washington State Department of 
Health.
outcome measures
ED visits were defined as an encounter that had at least one 
charge originating from the ED, regardless of whether it resulted 
in inpatient admission. Some encounters may have been counted 
as both an ED visit and an inpatient admission, but each metric 
was analysed separately. Index encounters were defined as ED 
visits or inpatient admissions (1) beginning on or before the 
randomisation date and (2) concluding on or after the rando-
misation date. ED visits and inpatient admissions were counted 
separately and included all encounters for any principal diagnosis 
with admission/visit dates occurring after the discharge date of 
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Table 1 Participant demographic characteristics, opioid use patterns, overdose history and risk and protective factors
Intervention Comparison Total
n=115 n=126 n=241
Age mean SD 40.2 11.5 42.3 11.5 41.3 11.5
n % n % n %
Female 32 28 37 29 69 29
Hispanic 14 12 21 17 35 15
Race
  White 60 53 67 54 127 53
  Black 17 15 14 11 31 13
  Asian 0 0 2 2 2 1
  Hawaiian/Pacific Islander 0 0 2 2 2 1
  American Indian/Native Alaskan 6 5 6 5 12 5
  Other 13 11 14 11 27 11
  More than one race 18 16 19 15 37 16
Housing
  Permanent 29 25 44 35 73 30
  Impermanent 19 17 22 18 41 17
  Homeless 67 58 59 47 126 53
Education
 <High School 38 33 35 28 73 30
  High School 37 32 45 36 82 34
 >High School 40 35 46 37 86 36
Relationship
  Not in a relationship 86 75 83 66 169 71
  In a relationship 28 25 42 34 70 29
Employment
  Employed 9 8 9 7 18 8
  Unemployed 88 77 88 70 176 73
  Retired 6 5 4 3 10 4
  Unable to work 7 6 22 18 29 12
  Other*  5 4 2 2 7 3
Opioid type
  Pharmaceutical only 18 16 13 10 31 13
  Heroin and no opioid agonist therapy 67 58 74 59 141 59
  Heroin and opioid agonist therapy 24 21 24 19 48 20
  Opioid agonist therapy no heroin 6 5 15 12 21 9
Smoke/snort/inject opioids 94 82 101 80 195 81
# of days used opioids past
30 days mean SD
24.3 8.4 25.1 8.8 24.7 8.6
Know others with overdose education
  Yes 45 39 62 49 107 44
  No/do not know 69 60 64 51 133 55
Know others who have naloxone
  Yes 33 29 41 33 74 31
  No/do not know 82 71 85 67 167 69
Opioid overdose history
  Never overdosed 48 42 56 44 104 43
  Overdosed, not past 3 months 48 42 43 34 91 38
  Overdosed past 3 months 19 17 27 21 46 19
Used alone past 3 months 89 77 100 79 189 78
Always/sometimes use ___ within 2 hours of opioids
  Alcohol 36 31 54 43 90 37
  Sedatives/downers 48 42 61 48 109 45
  More than one kind of opioid 53 46 54 43 107 44
  Uppers: cocaine, methamphetamine, pharmaceutical 57 50 72 57 129 54
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Table 2 Opioid overdose events and censoring by randomisation status
Group Total n
opioid overdose event status by data source: n (%)
Mean days to first 
overdose event¶ 
First opioid 
overdose in uW 
Medicine*
First opioid 
overdose in 
ChArs† 
First opioid 
overdose fatality 
in Doh‡ 
non-overdose 
fatality in Doh‡ 
no event prior to 
censoring at study 
end§ 
Comparison group 126 21 (16.7) 6 (4.8) 6 (4.8) 7 (5.6) 86 (68.3) 836
Intervention group 115 18 (15.7) 4 (3.5) 2 (1.7) 8 (7.0) 83 (72.2) 870
Combined 241 39 (16.2) 10 (4.2) 8 (3.3) 15 (6.2) 169 (70.1) 852
*Local inpatient admission or emergency department visit.
†Statewide hospital discharge for inpatient admission or observation visit.
‡Death certificate data, Department of Health.
§Available follow-up time: 272–1064 days.
¶Mean is underestimated because the largest observed analysis time is censored.
CHARS, Comprehensive Hospital Abstract Reporting System; UW, University of Washington.
Table 3 Annual local healthcare utilisation (all cause) after study enrolment by randomisation status
Group
emergency department visits* Inpatient admissions
Median annual 
rate IQr
Mean annual 
rate† 95% CI
Median annual 
rate IQr
Mean annual 
rate† 95% CI
Comparison group 2.72 5.49 4.85 3.96 to 5.93 0.43 1.50 1.05 0.80 to 1.39
Intervention group 2.42 7.35 4.96 4.04 to 6.10 0.39 1.80 1.29 0.95 to 1.76
Combined 2.57 6.93 4.90 4.25 to 5.66 0.41 1.52 1.17 0.95 to 1.44
Note: r ate differences between the intervention and comparison groups were not statistically significant. 
*Regardless of discharge status (may have resulted in inpatient admission).
†Mean rate per person-year calculated using negative binomial regression with time at-risk exposure variable for available follow-up time (272–1064 days, censored at death or 
31 December 2015).
the index visit through 31 December 2015. Index encounters 
were excluded from outcome encounter counts and excluded 
from consideration as the first opioid overdose event (described 
below), because the need for these encounters was evidenced 
prior to the intervention and hence not properly considered an 
outcome.
All three administrative data sources (ie, UW Medicine, 
CHARS and death certificate data) were used jointly to iden-
tify the first opioid overdose event occurring after randomisa-
tion and discharge from the index encounter and censored at 
31 December 2015. Time to the first opioid overdose event was 
measured from randomisation to the date of the first-occurring 
qualifying event: (1) UW Medicine ED, inpatient or outpatient 
encounter for opioid overdose, (2) CHARS inpatient admis-
sion or observation stay for opioid overdose or (3) death from 
opioid overdose. The definitions for an opioid overdose based 
on ICD-9 (International Classification of Diseases) and ICD-10 
codes across datasets are detailed in the online supplement.
sample size
Power calculations were based on the estimated annual overdose 
rate of 20% for heroin users and 10% for pharmaceutical opioid 
users (seen in the ED) and reduction in opioids overdoses of 50% 
due to the intervention. The sample size for heroin users to meet 
these parameters was 219 with 1 year of follow-up for overdose. 
For pharmaceutical users with an estimated annual overdose rate 
of 10%, we would require roughly twice the number of subjects 
or double the follow-up time to have the same number of over-
dose events.
Data analysis
Healthcare utilisation outcomes (ie, number of ED visits and 
number of inpatient admissions) were analysed using negative 
binomial regression with robust variance estimates and a time 
at-risk exposure adjustment for available follow-up time. Mean 
rates per person-year were calculated using these models.
Kaplan-Meier survival function curves were used to depict 
time from randomisation to the first opioid overdose event, 
with days of follow-up as the time scale. Death due to causes 
other than opioid overdose was treated as a censoring event but 
cannot be considered independent of randomisation assignment. 
We therefore treated death due to causes other than opioid over-
dose as a competing risk, using competing risk survival analysis 
models to analyse time from randomisation to the first opioid 
overdose event.28 The STATA command -stcrreg- (based on the 
Fine and Gray semiparametric method) was used to produce 
sub-HRs (SHR).29 30
All statistical tests were two tailed, with statistical significance 
defined as P≤0.05. Analyses were performed using Stata/MP 
V.13.1 for Windows. The study was registered at  clinicaltrials. 
gov (NCT01788306).
resulTs
study enrolment
Enrollment occurred between 31 January 2013 and 3 April 
2015, allowing for at least 272 and up to 1064 days of follow-up, 
which ended on 31 December 2015. Participant enrolment, allo-
cation and analysis are outlined in the Consolidated Standards of 
Reporting Trials (CONSORT) diagram in figure 1, as are reasons 
for study exclusion. Among the 430 assessed for study eligibility, 
256 were enrolled and randomised, with 125 allocated to the 
intervention and 131 to the comparison group.
The study underenrolled compared with the original study 
design of 500 heroin and 500 pharmaceutical opioid users. 
The randomisation process appears to have achieved sufficient 
balance; baseline characteristics in table 1 are comparable (all 
P values >0.05). For these analyses only those who provided 
consent to access secondary data were included: 115 in the 
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Figure 2 Time to the first opioid overdose event (encounter or death) 
(n=241).
intervention arm and 126 in the comparison group, a combined 
total of 241. The care setting in which participants were recruited 
included ED (n=149), respite care (n=37) and hospital inpa-
tient (n=55) and did not differ significantly by study assignment. 
We identified potential subjects as quickly as possible and among 
those enrolled in respite care 89% had their baseline assessment 
completed within 3 days of starting the assessment (maximum 5 
days) and among inpatients 98% had the assessment completed 
within 2 days (maximum 3).
Characteristics of intervention and comparison groups
The majority of participants were male, white, non-Hispanic, 
homeless, not in a relationship, unemployed, used heroin and 
not in OAT and used opioids by routes of ingestion including 
smoking, snorting or injecting (table 1). The mean number of 
days that opioids were used in the past 30 days was 24.7 (8.6 
SD) with a median of 30. Protective factors for overdose were 
reported by a minority of participants including others in their 
life having overdose education or possessing naloxone. The 
majority had a history of an opioid overdose, 19% in the prior 
3 months and 38% sometime prior to the most recent 3 months. 
The vast majority, 78%, reported using opioids alone sometimes 
or always in the prior 3 months, and many reported using a range 
of other substances within 2 hours of using opioids. A substan-
tial minority reported having had prior overdose education and 
knowing others who had naloxone.
MI fidelity
MI Spirit was calculated on 61 intervention sessions (out of 76 
recordings), with an average score of 4.23 (out of 5). Recorded 
length across the 76 sessions for the overdose education and 
brief behaviour change counselling content averaged 27 min, 
with length ranging from 10 min to 55 min.
overdose events by intervention assignment
Opioid overdose events and censoring by randomisation status 
are presented in table 2 and indicate that 23.7% of partici-
pants had at least one overdose event of some type, 6.2% had a 
non-overdose fatality and 70.1% had no observed event prior to 
censoring at the end of study follow-up.
healthcare utilisation by intervention assignment
The majority (55%) of all participants had a hospital admission 
during the follow-up period with an average annual rate of 1.17 
(95% CI 0.95 to 1.44) visits and with no significant difference 
between the intervention and comparison groups (table 3). A 
substantial majority (85%) of all participants had a subsequent 
ED visit during the follow-up period, with an average annual 
rate of 4.90 (95% CI 4.25 to 5.66) visits and with no significant 
difference by intervention assignment.
Time to first overdose by intervention assignment
In the competing risk regression analysis, the difference in the 
time to first overdose event was not significantly lower for the 
intervention group relative to the comparison group (SHR: 0.83; 
95% CI 0.49 to 1.40). These data are presented as a survival 
curve in figure 2.
DIsCussIon
In this study of patients at high risk for opioid overdose 
presenting for or soon after emergency care, an overdose 
prevention intervention was found to have no statistically 
significant impact on subsequent overdoses, either positive 
or negative. This null finding is perhaps not surprising given 
the medical and social acuity of the population in terms of 
homelessness, drug use and other health and social issues. A 
brief, one-time intervention in acute care settings or subse-
quent to receiving acute care may not be sufficient to reduce 
serious overdose events. The multipart intervention was likely 
more intensive and time consuming than most overdose educa-
tion and naloxone distribution programme in community or 
medical settings, although there is great heterogeneity in these 
interventions.
Population-based studies have found decreased mortality 
rates associated with distributing naloxone to illicit drug 
users.25 Estimates of the lifetime impact of naloxone distri-
bution to individual heroin users are modest, a 6% mortality 
reduction.31 Naloxone distribution programmes provide clear 
life-saving benefits; however, they are also insufficient to 
substantially address opioid overdose alone. Brief interven-
tions in the ED have shown modest benefits in decreasing 
opioid-related risk behaviours and drug use; however, these 
studies were of those with recent prescription opioid misuse 
and used a much broader definition of overdose that was not 
limited to opioids.13 14 We did not use self-report of overdose 
as an outcome as follow-up rates at each time point were less 
than 50%, perhaps due to the high levels of housing imper-
manence. We chose to enrol a high-acuity population, despite 
knowing that this might lessen the impact of the intervention 
and lower follow-up rates as we felt it was important to enrol a 
population representative of that seen in the care settings. It is 
possible that the informational flyer provided to the compar-
ison group combined with the substantial increases in take-
home naloxone within the community was sufficient to reduce 
any differential effect of the intervention.
The statistical power to detect differences was limited by 
the sample size and given the modest, though significant, 
impact of naloxone distribution found in other studies likely 
was an important limitation in our ability to find any potential 
impact of our intervention. We attempted to address this by 
adding measures of non-fatal overdose as an outcome because 
studies with an outcome of fatal overdose require sample 
sizes of many thousands,26 but we could only capture over-
dose events that resulted in an outpatient visit, ED or hospital 
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original article
What is already known on the subject
 ► Opioid overdoses are increasing rapidly.
 ► Overdose education and take-home naloxone decrease 
population rates of overdose.
What this study adds
 ► A brief behavioural-educational intervention combined with 
an offer of naloxone did not reduce opioid overdose events 
or health care utilisation among a high-acuity population 
seen in postacute care.
 ► Patients seen in acute care settings at elevated risk 
for overdose had very high rates of subsequent 
emergency department visits and hospitalisations and 
warrant more intensive interventions.
 ► Clinical trials of emergent issues may be impacted by rapid 
changes in the public health and healthcare environments.
admission. Naloxone distribution studies are further limited in 
that naloxone distributed to one person is often administered 
to another, potentially underestimating the total impact of the 
intervention. We did not account for heroin users being on 
OAT in our sampling design, which is a complicating issue in 
that research indicates being on OAT reduces fatal overdose 
occurrence, potentially reducing the overdose event rate and 
the statistical power to detect any differences.32 A subanalysis 
of the time to overdose event adjusting for opioid-use type did 
not significantly impact results (data not shown).
Study recruitment was challenging given the care settings 
and the acuity of the population, acute care settings are very 
hectic and complicated the logistics identifying, approaching 
and enrolling subjects in a study. Medical providers were reori-
ented to the study multiple times in order to reinforce that 
pharmaceutical opioid users, including those with a prescrip-
tion for the medications, were indeed eligible for the study. 
There were also challenges in identifying pharmaceutical users 
due to very limited use of and access to Washington State’s 
prescription drug monitoring programme (PDMP) by medical 
providers at the time of the study. Study staff were precluded 
from accessing the PDMP for research purposes per state law.
In addition to overdose education, counselling and naloxone, 
other more robust interventions such as direct referral and provi-
sion of housing and OAT medications may be necessary to have 
a clinically significant impact on opioid overdoses for this high-
acuity population served in acute care settings. The ED is a chal-
lenging setting for delivering an intervention logistically, in terms 
of timing and space constraints, and due to the medical state of 
patients. The most common reasons for refusing the screening 
interview (n=510), among those approached (n=936) were ‘not 
interested’ (49%), ‘not feeling well’ (39%) and ‘no time’ (8%). 
Only a small proportion of those enrolled in the study were seen 
for an opioid overdose (12%). Recent findings suggest that brief 
overdose and naloxone training is sufficient, and it appears that a 
population level mortality benefit is associated with higher rates of 
naloxone distribution in a community.25 33–40 Therefore, ED over-
dose prevention interventions might reasonably be limited to brief 
education with the direct provision of take-home naloxone. Future 
research on the impact of a more modest intervention with a larger 
number of acute care participants may be worthwhile.
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